Page last updated: 2024-11-04

n-acetylsphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-acetylsphingosine: inhibits phospholipase D [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5497136
CHEMBL ID105867
CHEBI ID46979
CHEBI ID92736
SCHEMBL ID1191825
MeSH IDM0178314

Synonyms (67)

Synonym
BRD-K41707108-001-02-3
BRD-K41707108-001-03-1
IDI1_034035
HSCI1_000073
BSPBIO_001565
3102-57-6
acetamide, n-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-, [r-[r*,s*-(e)]]-
acetamide, n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-
c2ceramide
cmc_12046
acetamide, n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]- (9ci)
d-erythro-c2-ceramide
d-erythro-n-acetylsphingosine
c2-ceramide
cmc_12047
c2-cer
acetamide, n-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-, (e)-d-erythro- (8ci)
d-erythro-1,3-dihydroxy-2-acetamido-trans-4-octadecene
cmc_12038
CHEBI:46979 ,
n-(acetyl)-sphing-4-enine
NCGC00024763-03
n-acetoyl-d-erythro-sphingosine
n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]acetamide
n-acetyl-d-erythro-sphingosine
n-[(2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]acetamide
n-acetylsphingosine
c2 ceramide
acetamide, n-(2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-, (r-(r*,s*-(e)))-
HMS1989O07
n-acetyl-d-sphingosine
195194-58-2
n-acetylspingosine
CHEMBL105867
BML3-C10
HMS1361O07
HMS1791O07
n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]acetamide
cer(d18:1/2:0)
n-(acetyl)-ceramide
LMSP02010014
unii-8ytc7r47cw
8ytc7r47cw ,
AKOS015915613
SCHEMBL1191825
c-2 ceramide
BLTCBVOJNNKFKC-QUDYQQOWSA-N
n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]acetamide
HMS3649E05
HMS3402O07
mfcd00153903
sr-01000597683
SR-01000597683-1
CHEBI:92736
J-018227
c2 ceramide (d18:1/2:0), n-acetoyl-d-erythro-sphingosine, powder
acetamide, n-((1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl)-
n-acetyl-c18-sphingosine
HMS3675F19
Q27120742
SR-01000946564-1
sr-01000946564
HMS3411F19
DTXSID201016802
MS-25224
HY-101180
CS-0020949

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We previously demonstrated the adverse effect of TNF in the process of reendothelialization as well as the dependence of its effect on cell-cycle regulation."( Loss of cyclin A and G1-cell cycle arrest are a prerequisite of ceramide-induced toxicity in human arterial endothelial cells.
Axel, DI; Karsch, KR; Mayer, P; Shook, KS; Spyridopoulos, I; Viebahn, R, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Treatment of the tumour cells with neutral sphingomyelinase drastically reduced the amount of wild-type p53 fibrosarcoma cell proliferation over 72 h in a clear dose-response (0."( Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells.
Aalame, N; Bodis, S; Glanzmann, C; Pruschy, M; Resch, H; Shi, YQ, 1999
)
0.3
" GCSF at a dosage of 30 to 100 ng/mL, a concentration range that primes superoxide release, stimulated a 60% to 100% increase in gelatinase release from tertiary granules but did not stimulate lactoferrin release from secondary granules."( Granulocyte colony-stimulating factor primes NADPH oxidase in neutrophils through translocation of cytochrome b(558) by gelatinase-granule release.
Boxer, LA; Hinkovska-Galcheva, V; Mansfield, PJ; Shayman, JA, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acylsphingosineThe parent compounds of the ceramide family, composed of sphingosine having an unspecified fatty acyl group attached to the nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency3.26430.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1162037Antiproliferative activity against human HepG2 cells after 24 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Flexible, polymer-supported synthesis of sphingosine derivatives provides ceramides with enhanced biological activity.
AID393059Cytotoxicity against human MDA-MB-231 cells after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1732283AUC(0 to t) in BALB/c mouse at 10 mg/kg, iv2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID308458Cytotoxicity against NCI-H358 cells assessed as cell survival by SRB assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and preliminary biological evaluation of a novel triazole analogue of ceramide.
AID125187Apoptogenic activity against Molt cells after 24 hr treatment at concentration 30 uM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and apoptogenic activity of fluorinated ceramide and dihydroceramide analogues.
AID157400Apoptogenic activity against peripheral blood lymphocytes after 24 hr treatment at concentration 30 uM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and apoptogenic activity of fluorinated ceramide and dihydroceramide analogues.
AID1627823Induction of vacuolation in mouse FL5.12A cells assessed as vacuolation score at 50 uM measured at 3 hrs by fluorescence microscopic analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID95642Apoptogenic activity against K-422 cells after 24 hr treatment at concentration 30 uM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Synthesis and apoptogenic activity of fluorinated ceramide and dihydroceramide analogues.
AID1732280Tmax in BALB/c mouse at 50 mg/kg, ip2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID393060Cytotoxicity against human SKBR3 cells after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1732285AUC(0 to infinity) in BALB/c mouse at 10 mg/kg, iv2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID1627824Downregulation of CD8 expression level in mouse FL5.12A cells at 50 uM measured at 3 hrs by flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1732286Half life in BALB/c mouse at 50 mg/kg, ip2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID127917Concentration at which compound suppressed the MLR response (mixed leukocyte reaction) in murine spleen cells; range = 80 ng/mL to 2 ug/mL1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Effects of alpha- and beta-galactosylated C2-ceramides on the immune system.
AID393065Induction of early apoptosis in human SupT1 cells after 24 hrs using annexin V-FITC staining by FACS2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID393064Induction of apoptosis in human SupT1 cells at 50 uM after 24 hrs using DiOC6 staining by FACS2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1732282AUC(0 to t) in BALB/c mouse at 50 mg/kg, ip2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID393062Induction of early apoptosis in human SupT1 cells at 50 uM after 24 hrs using annexin V-FITC staining by FACS2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1162039Antiproliferative activity against human HL60 cells after 24 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Flexible, polymer-supported synthesis of sphingosine derivatives provides ceramides with enhanced biological activity.
AID393057Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID44025In vitro growth inhibitory effect in human T-cell acute leukemia cells CCRF-CEM2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues.
AID81276Apoptotic activity against HL-60 (Human leukemia) cell after 6 hr of stimulation measured by MTT assay2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis of non-natural C2-homo-ceramide and its apoptotic activity against HL-60 cells.
AID1732281Cmax in BALB/c mouse at 50 mg/kg, ip2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID44199Percentage increase in caspase-3 activity of CCRF-CEM human T-leukemia cells.2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues.
AID1732287Half life in BALB/c mouse at 10 mg/kg, iv2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID308457Cytotoxicity against HCT116 cells assessed as cell survival by SRB assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and preliminary biological evaluation of a novel triazole analogue of ceramide.
AID401377Toxicity against Ulva conglobata at 50 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID1732288Apparent clearance in BALB/c mouse at 10 mg/kg, iv2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID393067Cytotoxicity against NHDF after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID308459Cytotoxicity against K562 cells assessed as cell survival by MTT assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and preliminary biological evaluation of a novel triazole analogue of ceramide.
AID393058Cytotoxicity against human MCF7 cells after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1732284AUC(0 to infinity) in BALB/c mouse at 50 mg/kg, ip2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID1162038Antiproliferative activity against rat PC12 cells after 24 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Flexible, polymer-supported synthesis of sphingosine derivatives provides ceramides with enhanced biological activity.
AID1627820Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID393066Induction of apoptosis in human SupT1 cells after 24 hrs using DiOC6 staining by FACS2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID1732225Antiproliferative activity against human HT-29 cells measured after 72 hrs by sulforhodamine B assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (498)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's159 (31.93)18.2507
2000's262 (52.61)29.6817
2010's68 (13.65)24.3611
2020's9 (1.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other504 (99.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]